Impact of Calvimax-D on the Dissolution Profile of Rocovus

Abstract

The aim of this study is to find the impact of calcium-vitamin D supplement on the dissolution profile of Rocovus® (rosuvastatin calcium). Rosuvastatin is a cholesterol lowering drug and is used in hyperlipidemia and dyslipidemia. On the other hand, calcium-vitamin D supplements are used in patients who lack in calcium and vitamin D. Dissolution test of these two agents are performed to observe if there is any change in their release pattern when they are combined than they are dissolved individually. The test is performed under optimum conditions. The dissolution test was performed by using distilled water (as dissolution medium) with USP dissolution apparatus II. The dissolution tester was run in 37°C temperature at 50 rpm for 60 minutes. The absorbance of the samples were measured by UV-spectrophotometer at 241 nm. A standard curve equation of Rosuvastatin was established for the calculation of percent dissolved amount of drug. The dissolution of individual Rocovus® tablets and also combination with the Calcium and Vitamin D supplement drugs were determined after 10, 20, 30, 40, 50, 60 minutes. Six samples of each individual Rocovus® tablets and combination with the Calcium and Vitamin D supplement drugs were subjected to determine the dissolution profile. It was observed that at 10 minutes the average percent of drug release was 40.74% that create an impact of 24.36%. After 60 minutes the average percent of drug release was 50.03% and the impact of dissolution altered was 29.90%. So, it was clear that with increasing time the dissolution or the drug release of Rocovus® is decreased when it is combined with calcium and vitamin D supplement. The reason for such decrease in drug release is due to common ion effect. Finally, it can be concluded that rosuvastatin should not be co-administered with calcium-vitamin D supplement.